This randomized, multi-center, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
595
Positive symptoms factor score assessed by Positive and Negative Syndrome Scale (PANSS)
Time frame: Change from baseline to Week 12
Safety (incidence of adverse events)
Time frame: Week 12
Symptom domains of schizophrenia using Positive and Negative Syndrome Scale (PANSS)
Time frame: Change from baseline to Week 12
Disease improvement on Clinical Global Impression - Improvement (CGI-I) symptoms scale
Time frame: Change from baseline to Week 12
Disease severity on Clinical Global Impression - Severity (CGI-S) symptoms scale
Time frame: Change from baseline to Week 12
Safety (incidence of adverse events)
Time frame: 60 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Little Rock, Arkansas, United States
Unnamed facility
Little Rock, Arkansas, United States
Unnamed facility
Buena Park, California, United States
Unnamed facility
Cerritos, California, United States
Unnamed facility
Downey, California, United States
Unnamed facility
La Palma, California, United States
Unnamed facility
Pasadena, California, United States
Unnamed facility
Pico Rivera, California, United States
Unnamed facility
Miami, Florida, United States
Unnamed facility
Miami, Florida, United States
...and 111 more locations